🔗 Share this article

As the United States undertakes unprecedented adjustments to its vaccine schedules, an unexpected name appears unexpectedly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by questioning coronavirus vaccinations during the global health crisis and has focused upon alleged fatalities following COVID-19 vaccination in her short position at the FDA.

Proposed Overhauls to Pediatric Vaccine Schedule

Agency leaders had intended to unveil sweeping changes to the pediatric vaccine schedule in December, bringing the US with the Danish national calendar, sources say – a significant shift that would place the US out of step with much of the global community with no evidence for benefit. The planned update has been postponed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to speak at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to head the division this calendar year.

A New Direction at the Regulatory Body

This interim role may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the agency – and it signals a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric immunization guidelines in the US to become more similar to Denmark, a nation with nationalized medicine and a citizenry about the population of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccines – typically the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Expertise

Høeg has little discernible track record in drug development, oversight or administrative roles, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for running the CDER, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a major agency. She lacks background in drug approvals.”

Previous heads of the center would “understand laws and regulations and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the type of experience that previous people who ran the center have had.”

This division has an vast portfolio at the agency, Woodcock pointed out.

“Everybody just focuses on the novel medication approvals, but the generic program authorizes numerous generic drugs. There’s a biologic copycat branch, over-the-counter program and other areas, and all of those must be supervised,” Woodcock explained. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a major administrative element to the role, which supervises over 5,000 personnel. “It’s a massive management job, if you perform it correctly,” she concluded.

Response and Controversial Programs

When asked about questions about Høeg’s qualifications and whether this selection indicates increased cooperation among FDA leaders on immunizations, a press secretary responded that the “concerns are based on incorrect assumptions”.

“Her experience matches the functions of her role,” the representative explained, pointing to the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a contentious one-day medication authorization process that allegedly troubled her predecessors. “By what process are these therapies being chosen for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There is a lot of secrecy happening at the agency right now.”

Overall, he remarked, “the FDA appears to be shifting towards less stringent oversight of pharmaceuticals, with the exception of vaccines.”

Documented Past Work on Vaccines

Concerning vaccines, Dr. Høeg has a clearer, if concerning, past, critics said. She released a research paper using non-validated public submissions to estimate the rate of heart inflammation after Covid vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have altered data to suggest Covid vaccinations are more dangerous than they are.

Included in her “policy goals” for the new federal leadership featured altering rules for novel immunizations and ending “unnecessary” immunizations, she stated post-election on a online show. At the agency, Høeg has according to sources floated the idea of excluding adolescent males from receiving Covid vaccines.

“She is an all-around dogmatist who begins with her beliefs and works backwards to fit the data in a highly misleading, untruthful way,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other skeptics, {like|